JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced that results from the ADAGIO study will be presented at the 12th Congress of European Federation of Neurological Societies (EFNS) on August 26, 2008 in Madrid, Spain. The ADAGIO delayed-start study was designed to demonstrate that AZILECT® can slow down the progression of Parkinson’s disease. As previously announced, the 1mg dose met all three primary end points, as well as the secondary end point, all with statistical significance.
